Login to Your Account

Messenger for Others in the Space?

A 'Moderna' Cinderella Story: AstraZeneca's $240M Up Front

By Randy Osborne
Staff Writer

Friday, March 22, 2013
Moderna Therapeutics Inc.'s major win, in the form of a $240 million up-front licensing deal with battered AstraZeneca plc for technology still at the preclinical stage, put the spotlight on messenger RNA therapy (mRNA) and sparked guesswork about whether the wager by the pharma giant can bring enough revenue soon enough.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription